In a recent study at the Cancer Science Institute of Singapore and elsewhere, researchers discovered a protein that drives the growth of cancers of the liver by changing the genetic code.
The protein, death-associated protein 3 (DAP3), represses an RNA editing that normally corrects the genetic code to ensure that genes are expressed correctly.
By inhibiting RNA editing, DAP3 acts as an oncogene—a gene that has the potential to cause cancer.
This discovery offers the potential of developing novel drugs that target DAP3 for cancer treatment.
The study is published in Science Advances. One author is Assistant Professor Polly Chen.
RNAs are one of the most important classes of molecules in cells. They not only convert the genetic information stored in DNA to proteins but also play critical regulatory roles in various biological processes.
RNA editing is a process in which RNA is changed after it is made from DNA, resulting in an altered gene product.
In humans, the most common type of RNA editing is A-to-I editing, which is mediated by ADAR proteins (ADAR1 and ADAR2).
In the past decade, many studies had reported that the accumulation of deleterious changes in A-to-I RNA editing can trigger a cell to develop into cancer.
In the study, the research team aimed to understand how DAP3 regulates this process in cancer cells.
The team found that DAP3 could destroy the binding of ADAR2 protein to its target RNAs, thereby inhibiting the A-to-I RNA editing in cancer cells.
This suppression is likely to be one of the pathways by which DAP3 could promote cancer development.
Their analysis also showed that the expression of DAP3 is elevated in 17 types of cancer.
Further experiments demonstrated that DAP3 acted as an oncogene in esophageal cancer and liver cancer cells.
Interestingly, the team also identified the gene PDZD7, one of DAP3-inhibited editing targets, and discovered that altered editing of PDZD7 generated a new PDZD7 protein product which contributed to the DAP3-driven tumor growth.
Overall, these observations shed light on the complexity of the regulation of the A-to-I RNA editing process in cancer cells, and suggest that DAP3 could be a promising target for future cancer drug development.
Copyright © 2020 Knowridge Science Report. All rights reserved.